{"id":26631,"date":"2021-09-16T14:21:56","date_gmt":"2021-09-16T12:21:56","guid":{"rendered":"https:\/\/www.transgene.com\/?p=26631"},"modified":"2026-03-23T16:50:43","modified_gmt":"2026-03-23T15:50:43","slug":"bt-001","status":"publish","type":"post","link":"https:\/\/www.transgene.com\/fr\/bt-001\/","title":{"rendered":"produits : BT-001"},"content":{"rendered":"\n<div id=\"tetContainer\" class=\"wp-block-uagb-container uagb-block-ec6f09b8 alignfull uagb-is-root-container\">\n<div class=\"bgImg-01 wp-block-columns eplus-wrapper is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\" id=\"tgTetContainer\">\n<div class=\"wp-block-column eplus-wrapper is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:100%\" id=\"degHaut\">\n<div class=\"wp-block-columns eplus-wrapper is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\" id=\"degbas\">\n<div class=\"wp-block-column eplus-wrapper is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:100%\" id=\"ongletBas\"><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n<div class=\"maxWidth wp-block-columns eplus-wrapper is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column eplus-wrapper is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:33.33%\">\n<div id=\"tgProduitIntro\">&nbsp;<\/div>\n<div id=\"titleTG\">\n<h1>BT-001<\/h1>\n<div id=\"myvacLogo\"><img decoding=\"async\" class=\"alignnone size-full wp-image-35801\" src=\"https:\/\/www.transgene.com\/wp-content\/uploads\/invirio-Q2.svg\" alt=\"\"><\/div>\n<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-column eplus-wrapper is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:66.66%\">\n<div id=\"ProduitIntro\" class=\"maxWidthTxt\">\n<h2><strong>BT-001<\/strong> est un <strong>virus oncolytique multifonctionnel<\/strong> issu de la plateforme Invir.IO<sup>\u00ae<\/sup>.<\/h2>\n<h2><strong>Deux \u00ab armements \u00bb sp\u00e9cifiques<\/strong> ont \u00e9t\u00e9 int\u00e9gr\u00e9s \u00e0 son ADN : un <strong>anticorps anti-CTLA4<\/strong> d\u00e9velopp\u00e9 par BioInvent et la <strong>cytokine GM-CSF<\/strong> pour activer la r\u00e9ponse immunitaire.<\/h2>\n<p>&nbsp;<\/p>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n<div class=\"relanceContainer eplus-Hznsb4 eplus-wrapper wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\">\n<div class=\"eplus-n4sHS9 eplus-wrapper wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:100%\">\n<div class=\"eplus-6DgPNw eplus-wrapper wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\">\n<div class=\"eplus-EH3sBp eplus-wrapper TGrelance wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:100%\">\n<div class=\"BG-dna\">\n<h2 class=\"eplus-ATU6ZX eplus-wrapper\" style=\"color: white;\">D\u00e9truire de mani\u00e8re cibl\u00e9e les cellules canc\u00e9reuses<\/h2>\n&nbsp;<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n<div class=\"maxWidth wp-block-columns eplus-wrapper is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column eplus-wrapper is-layout-flow wp-block-column-is-layout-flow\">\n<div class=\"RubTitle rubArticle\">\n<div class=\"HpNews-container\">\n<div class=\"HpNews-content \"><a class=\"btnVideo\" title=\"\" href=\"https:\/\/vimeo.com\/615834632?width=640&amp;height=480\" rel=\"wp-video-lightbox\">D\u00e9couvrez comment fonctionne BT-001 (vid\u00e9o)<\/a>\n<div class=\"asterix astMar\">* cookies analytiques requis<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n<div class=\"mobilMargin wp-block-column eplus-wrapper is-layout-flow wp-block-column-is-layout-flow\">\n<p>D\u00e9riv\u00e9s de la <strong>plateforme Invir.IO<sup>\u00ae<\/sup><\/strong>, nos virus oncolytiques <strong>infectent, se multiplient de mani\u00e8re sp\u00e9cifique et induisent la lyse des cellules tumorales <\/strong>(ou oncolyse).<\/p>\n<p>&nbsp;<\/p>\n<p>Ces virus int\u00e8grent \u00e9galement des armes anticanc\u00e9reuses dans leur g\u00e9nome, ce qui leur permet de <strong>moduler le microenvironnement tumoral<\/strong>.<\/p>\n<p>&nbsp;<\/p>\n<p>Ces diff\u00e9rents m\u00e9canismes conduisent \u00e0 la destruction des cellules tumorales et \u00e0 l\u2019activation du syst\u00e8me immunitaire, tout en <strong>pr\u00e9servant les cellules saines du patient<\/strong>.<\/p>\n<\/div>\n<\/div>\n\n\n\n<div class=\"relanceContainer eplus-Hznsb4 eplus-wrapper wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\">\n<div class=\"eplus-n4sHS9 eplus-wrapper wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:100%\">\n<div class=\"eplus-6DgPNw eplus-wrapper wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\">\n<div class=\"eplus-EH3sBp eplus-wrapper TGrelance wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:100%\">\n<div class=\"BG-dna\">\n<h2 class=\"eplus-ATU6ZX eplus-wrapper\" style=\"color: white;\">Le traitement par BT-001 a permis de transformer les tumeurs \u00abfroides\u00bb en tumeurs \u00abchaudes\u00bb<\/h2>\n&nbsp;<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n<div class=\"maxWidth wp-block-columns eplus-wrapper is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\">\n<div class=\"mobilMargin wp-block-column eplus-wrapper is-layout-flow wp-block-column-is-layout-flow\">\n<p>Les donn\u00e9es pr\u00e9liminaires pr\u00e9sent\u00e9es lors du congr\u00e8s ESMO 2025 montrent une <strong>activit\u00e9 antitumorale locale, \u00e0 distance et durable chez les patients atteints de tumeurs avanc\u00e9es en \u00e9chec th\u00e9rapeutiques.<\/strong><\/p>\n<p>&nbsp;<\/p>\n<p>Le BT-001 se r\u00e9plique dans la tumeur et <strong>les transg\u00e8nes sont exprim\u00e9s<\/strong>, sans \u00eatre d\u00e9tect\u00e9s dans le sang. Le BT-001, seul ou en combinaison avec le pembrolizumab, a \u00e9t\u00e9 <strong>bien tol\u00e9r\u00e9 et a montr\u00e9 les premiers signes d\u2019efficacit\u00e9<\/strong> avec des r\u00e9ponses cliniques chez 2 des 6 patients n\u2019ayant pas r\u00e9pondu aux traitements pr\u00e9c\u00e9dents, lorsqu\u2019il \u00e9tait administr\u00e9 en combinaison avec le pembrolizumab.<\/p>\n<p>&nbsp;<\/p>\n<p><strong>Ces r\u00e9gressions tumorales m\u00e9di\u00e9es par le syst\u00e8me immunitaire sont coh\u00e9rentes avec le m\u00e9canisme d\u2019action selon lequel BT-001, en combinaison avec pembrolizumab, transforme les tumeurs \u00ab froides \u00bb en tumeurs immunologiquement actives.<\/strong><\/p>\n<p>&nbsp;<\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-column eplus-wrapper is-layout-flow wp-block-column-is-layout-flow\">\n<div class=\"RubTitle rubArticle\">\n<div class=\"HpNews-container\">\n<h2>Faits marquants<br \/>de BT-001<\/h2>\n<div class=\"HpNews-content \"><a class=\" cgPdf\" title=\"\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20251019_BT001_ESMO2025.pdf\">T\u00e9l\u00e9charger le poster pr\u00e9sent\u00e9 \u00e0 l\u2019ESMO 2025 <\/a><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n<p class=\"maxWidth eplus-wrapper wp-block-paragraph\"><\/p>\n\n\n\n<div class=\"eplus-QPii9T eplus-wrapper maxWidth wp-block-columns alignfull is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\">\n<div class=\"eplus-Ty9XXX eplus-wrapper wp-block-column is-vertically-aligned-center is-layout-flow wp-block-column-is-layout-flow\">\n<div class=\"eplus-OqQ4Ro eplus-wrapper wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\">\n<div class=\"eplus-03Lz92 maxWidth eplus-wrapper wp-block-column is-layout-flow wp-block-column-is-layout-flow\"><\/div>\n<\/div>\n\n\n\n<div class=\"RubTitle rubArticle agreements\">\n<div class=\"HpNews-container\">\n<h2>Accords de collaboration<\/h2>\n<p>Transgene et BioInvent ont conclu un accord de collaboration clinique et de mise \u00e0 disposition de KEYTRUDA\u00ae (pembrolizumab) avec MSD, une marque d\u00e9pos\u00e9e de Merck &amp; Co, Inc. \u00e0 Rahway (\u00c9tats-Unis). La collaboration vise \u00e0 \u00e9valuer, dans un essai clinique de Phase I\/IIa, le virus oncolytique BT-001 en combinaison avec le traitement anti-PD-1 KEYTRUDA\u00ae de MSD pour le traitement de patients atteints de tumeurs solides.<\/p>\n<\/div>\n<\/div>\n<p>\u00a0<\/p>\n<\/div>\n<\/div>\n\n\n\n<div class=\"relanceContainer eplus-Hznsb4 eplus-wrapper wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\">\n<div class=\"eplus-n4sHS9 eplus-wrapper wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:100%\">\n<div class=\"eplus-6DgPNw eplus-wrapper wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\">\n<div class=\"eplus-EH3sBp eplus-wrapper TGrelance wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:100%\">\n<div class=\"BG-dna\">\n<h2 class=\"eplus-ATU6ZX eplus-wrapper\" style=\"color: white;\">Derniers r\u00e9sultats disponibles<\/h2>\n&nbsp;<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n<div class=\"maxWidth wp-block-columns eplus-wrapper is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\">\n<div class=\"eplus-EH3sBp eplus-wrapper  wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:100%\">\n<div class=\"RubTitle rubArticle\">\n<div class=\"HpNews-container\">\n<h2>Derni\u00e8res publications<\/h2>\n<div id=\"ancre-publi\" class=\" eplus-wrapper\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-36965\" style=\"max-width: 50px; margin: 20px 0 0 20px;\" src=\"https:\/\/www.transgene.com\/wp-content\/uploads\/scroll.jpg\" alt=\"\" width=\"145\" height=\"143\"> <ul class=\"lcp_catlist\" id=\"lcp_instance_0\"><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/cslide.ctimeetingtech.com\/esmo2025\/attendee\/confcal_2\/presentation\/list?q=955P\" title=\"Updated clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb,administered in combination with pembrolizumab in patients with advanced solid tumors\"><div class='catlistdate'>20 octobre 2025<\/div>  <div class='catlistTitle'>Updated clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb,administered in combination with pembrolizumab in patients with advanced solid tumors<\/div><\/a><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/cslide.ctimeetingtech.com\/esmo2024\/attendee\/confcal_2\/presentation\/list?q=1024P\" title=\"Initial clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered as single agent and in combination with pembrolizumab in patients with advanced solid tumors\"><div class='catlistdate'>14 septembre 2024<\/div>  <div class='catlistTitle'>Initial clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered as single agent and in combination with pembrolizumab in patients with advanced solid tumors<\/div><\/a><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.abstractsonline.com\/pp8\/#!\/10517\/presentation\/16993\" title=\"Comprehensive preclinical studies of BT-001: an oncolytic vaccinia virus armed with Treg-depleting @CTLA4 and GM-CSF\"><div class='catlistdate'>11 avril 2022<\/div>  <div class='catlistTitle'>Comprehensive preclinical studies of BT-001: an oncolytic vaccinia virus armed with Treg-depleting @CTLA4 and GM-CSF<\/div><\/a><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Poster-Euroocs-hle-2021-version-finale.pdf\" title=\"3D organoids derived from patients&rsquo; lung tumors: a tool for investigating the potential of oncolytic viruses\"><div class='catlistdate'>1<sup>er<\/sup> juillet 2021<\/div>  <div class='catlistTitle'>3D organoids derived from patients&rsquo; lung tumors: a tool for investigating the potential of oncolytic viruses<\/div><\/a><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/posters\/AACR2020-BT-001.pdf\" title=\"BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment\"><div class='catlistdate'>9 novembre 2020<\/div>  <div class='catlistTitle'>BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment<\/div><\/a><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Poster-EUROoCs-Final-version-Helene-LE-July-2020pptx_compressed.pdf\" title=\"Design of an Innovative Model to Improve Anticancer Therapeutic Treatment Based on a Vascularized 3D Organoids Derived from Patients\u2019 Lung Tumors for the Purpose of Precision Medicine\"><div class='catlistdate'>8 juillet 2020<\/div>  <div class='catlistTitle'>Design of an Innovative Model to Improve Anticancer Therapeutic Treatment Based on a Vascularized 3D Organoids Derived from Patients\u2019 Lung Tumors for the Purpose of Precision Medicine<\/div><\/a><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/posters\/AACR2020-BT-001.pdf\" title=\"BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment\"><div class='catlistdate'>22 juin 2020<\/div>  <div class='catlistTitle'>BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment<\/div><\/a><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Poster_Transgene_BT-001_Immuno_Onco_2020.pdf\" title=\"BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti- CTLA4 antibody and GM-CSF to target the tumor microenvironment\"><div class='catlistdate'>11 mars 2020<\/div>  <div class='catlistTitle'>BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti- CTLA4 antibody and GM-CSF to target the tumor microenvironment<\/div><\/a><\/li><\/ul><\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n<div class=\"eplus-EH3sBp eplus-wrapper  wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:100%\">\n<div class=\"RubTitle rubArticle\">\n<div class=\"HpNews-container\">\n<h2>Derniers communiqu\u00e9s de presse<\/h2>\n<div id=\"ancre-cp\" class=\" eplus-wrapper\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-36965\" style=\"max-width: 50px; margin: 20px 0 0 20px;\" src=\"https:\/\/www.transgene.com\/wp-content\/uploads\/scroll.jpg\" alt=\"\" width=\"145\" height=\"143\"> <ul class=\"lcp_catlist\" id=\"lcp_instance_0\"><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20261105_IST_BT001_FR.pdf\" title=\"Premier patient trait\u00e9 dans un essai de Phase 1 \u00e9valuant BT-001 de Transgene et BioInvent dans le cancer du rectum\"><div class='catlistdate'>5 novembre 2026<\/div>  <div class='catlistTitle'>Premier patient trait\u00e9 dans un essai de Phase 1 \u00e9valuant BT-001 de Transgene et BioInvent dans le cancer du rectum<\/div><\/a><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20251020_ESMO_Poster_FR.pdf\" title=\"Le virus oncolytique arm\u00e9 BT-001, d\u00e9velopp\u00e9 par Transgene et BioInvent, montre une activit\u00e9 antitumorale locale, \u00e0 distance et durable chez des patients atteints de tumeurs avanc\u00e9es en \u00e9chec th\u00e9rapeutique\"><div class='catlistdate'>20 octobre 2025<\/div>  <div class='catlistTitle'>Le virus oncolytique arm\u00e9 BT-001, d\u00e9velopp\u00e9 par Transgene et BioInvent, montre une activit\u00e9 antitumorale locale, \u00e0 distance et durable chez des patients atteints de tumeurs avanc\u00e9es en \u00e9chec th\u00e9rapeutique<\/div><\/a><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20240914_BT001_posterESMO2024_FR.pdf\" title=\"Le virus oncolytique BT-001 de Transgene et BioInvent montre une activit\u00e9 antitumorale prometteuse dans l&rsquo;\u00e9tude en cours de Phase I\/IIa dans les tumeurs solides r\u00e9sistantes\"><div class='catlistdate'>14 septembre 2024<\/div>  <div class='catlistTitle'>Le virus oncolytique BT-001 de Transgene et BioInvent montre une activit\u00e9 antitumorale prometteuse dans l&rsquo;\u00e9tude en cours de Phase I\/IIa dans les tumeurs solides r\u00e9sistantes<\/div><\/a><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20240909_-_Transgene_ESMO_abstract_BT001_FR.pdf\" title=\"Transgene et BioInvent pr\u00e9sentent des donn\u00e9es cliniques prometteuses de l&rsquo;essai de Phase I\/IIa du virus oncolytique BT-001 \u00e0 l&rsquo;ESMO 2024\"><div class='catlistdate'>9 septembre 2024<\/div>  <div class='catlistTitle'>Transgene et BioInvent pr\u00e9sentent des donn\u00e9es cliniques prometteuses de l&rsquo;essai de Phase I\/IIa du virus oncolytique BT-001 \u00e0 l&rsquo;ESMO 2024<\/div><\/a><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20240722_Transgene_ESMO_curtain_Raiser_BT001_FR.pdf\" title=\"Transgene et BioInvent pr\u00e9sentent un poster sur le virus oncolytique BT-001, \u00e0 l&rsquo;ESMO 2024\"><div class='catlistdate'>22 juillet 2024<\/div>  <div class='catlistTitle'>Transgene et BioInvent pr\u00e9sentent un poster sur le virus oncolytique BT-001, \u00e0 l&rsquo;ESMO 2024<\/div><\/a><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20231010-Transgene_BioInvent_BT-001_Phase_Ib_1erpatient_inclus_FR_VFinal.pdf\" title=\"Transgene et BioInvent &#8211; Un premier patient trait\u00e9 dans la partie B de l&rsquo;essai de Phase I \u00e9valuant le virus oncolytique BT-001 en combinaison avec KEYTRUDA\u00ae(pembrolizumab)\"><div class='catlistdate'>10 octobre 2023<\/div>  <div class='catlistTitle'>Transgene et BioInvent &#8211; Un premier patient trait\u00e9 dans la partie B de l&rsquo;essai de Phase I \u00e9valuant le virus oncolytique BT-001 en combinaison avec KEYTRUDA\u00ae(pembrolizumab)<\/div><\/a><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20230524-Transgene_BioInvent_BT-001_Phase_Ia-clinical_update_FR.pdf\" title=\"Transgene et BioInvent annoncent des r\u00e9sultats positifs pour l&rsquo;essai de Phase Ia du virus oncolytique BT-001 dans le traitement des tumeurs solides\"><div class='catlistdate'>25 mai 2023<\/div>  <div class='catlistTitle'>Transgene et BioInvent annoncent des r\u00e9sultats positifs pour l&rsquo;essai de Phase Ia du virus oncolytique BT-001 dans le traitement des tumeurs solides<\/div><\/a><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20221114-Transgene_JITC_Paper_award_FR.pdf\" title=\"Transgene et BioInvent remportent le prix du Meilleur Article dans la cat\u00e9gorie Immunoth\u00e9rapie oncolytique et locale d\u00e9cern\u00e9 par le JITC, pour leurs travaux sur BT-001\"><div class='catlistdate'>14 novembre 2022<\/div>  <div class='catlistTitle'>Transgene et BioInvent remportent le prix du Meilleur Article dans la cat\u00e9gorie Immunoth\u00e9rapie oncolytique et locale d\u00e9cern\u00e9 par le JITC, pour leurs travaux sur BT-001<\/div><\/a><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20220628-Transgene-BioInvent-BT-001-Merck-MSD-supply_agreement_pembrolizumab-FR.pdf\" title=\"Transgene et BioInvent annoncent la conclusion d&rsquo;un accord avec MSD de collaboration clinique et d&rsquo;approvisionnement pour \u00e9valuer BT-001 en combinaison avec KEYTRUDA\u00ae\"><div class='catlistdate'>28 juin 2022<\/div>  <div class='catlistTitle'>Transgene et BioInvent annoncent la conclusion d&rsquo;un accord avec MSD de collaboration clinique et d&rsquo;approvisionnement pour \u00e9valuer BT-001 en combinaison avec KEYTRUDA\u00ae<\/div><\/a><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20220627-Transgene_BioInvent_BT-001_clinical_update-FR.pdf\" title=\"Transgene et BioInvent pr\u00e9sentent les avanc\u00e9es positives de BT-001\"><div class='catlistdate'>27 juin 2022<\/div>  <div class='catlistTitle'>Transgene et BioInvent pr\u00e9sentent les avanc\u00e9es positives de BT-001<\/div><\/a><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20220309-Transgene_BioInvent_BT-001_AACR2022_Abstract-FR.pdf\" title=\"Transgene et BioInvent pr\u00e9senteront un poster \u00e0 l&rsquo;AACR 2022 sur BT-001, un virus oncolytique innovant\"><div class='catlistdate'>9 mars 2022<\/div>  <div class='catlistTitle'>Transgene et BioInvent pr\u00e9senteront un poster \u00e0 l&rsquo;AACR 2022 sur BT-001, un virus oncolytique innovant<\/div><\/a><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20220120-Transgene_BioInvent_BT-001_JITC_paper-FR.pdf\" title=\"Transgene et BioInvent publient dans le JITC des donn\u00e9es de preuve de concept pr\u00e9clinique du virus oncolytique BT-001\"><div class='catlistdate'>20 janvier 2022<\/div>  <div class='catlistTitle'>Transgene et BioInvent publient dans le JITC des donn\u00e9es de preuve de concept pr\u00e9clinique du virus oncolytique BT-001<\/div><\/a><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20211109-Transgene-BioInvent-SITC-BT-001-FR.pdf\" title=\"Transgene et BioInvent pr\u00e9sentent des donn\u00e9es pr\u00e9cliniques soulignant la forte activit\u00e9 antitumorale du virus oncolytique BT-001 au SITC 2021\"><div class='catlistdate'>9 novembre 2021<\/div>  <div class='catlistTitle'>Transgene et BioInvent pr\u00e9sentent des donn\u00e9es pr\u00e9cliniques soulignant la forte activit\u00e9 antitumorale du virus oncolytique BT-001 au SITC 2021<\/div><\/a><\/li><\/ul><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n<div id=\"footOrange\">\n<div class=\"masked\">\n<div class=\"TitteFullWidth \">\n<h2 class=\"eplus-ATU6ZX eplus-wrapper\" style=\"color: white;\">Nos virus oncolytiques multifonctionnels transforment le micro-environnement tumoral pour attaquer la tumeur sur plusieurs fronts<\/h2>\n<div class=\"breakEnd\">\u00a0<\/div>\n<div class=\"breakEnd\">\u00a0<\/div>\n<\/div>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>&nbsp; BT-001 BT-001 est un virus oncolytique multifonctionnel issu de la plateforme Invir.IO\u00ae. Deux \u00ab armements \u00bb sp\u00e9cifiques ont \u00e9t\u00e9 int\u00e9gr\u00e9s \u00e0 son ADN : un anticorps anti-CTLA4 d\u00e9velopp\u00e9 par BioInvent et la cytokine GM-CSF pour activer la r\u00e9ponse immunitaire. &nbsp; D\u00e9truire de mani\u00e8re cibl\u00e9e les cellules canc\u00e9reuses &nbsp; D\u00e9couvrez comment fonctionne BT-001 (vid\u00e9o) *&hellip; <a class=\"more-link\" href=\"https:\/\/www.transgene.com\/fr\/bt-001\/\">Poursuivre la lecture <span class=\"screen-reader-text\">produits : BT-001<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_coblocks_attr":"","_coblocks_dimensions":"","_coblocks_responsive_height":"","_coblocks_accordion_ie_support":"","_uag_custom_page_level_css":"","footnotes":""},"categories":[110],"tags":[],"class_list":["post-26631","post","type-post","status-publish","format-standard","hentry","category-outils-produits","entry"],"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false,"post-thumbnail":false},"uagb_author_info":{"display_name":"alcyon","author_link":"https:\/\/www.transgene.com\/fr\/author\/alcyon\/"},"uagb_comment_info":0,"uagb_excerpt":"&nbsp; BT-001 BT-001 est un virus oncolytique multifonctionnel issu de la plateforme Invir.IO\u00ae. Deux \u00ab armements \u00bb sp\u00e9cifiques ont \u00e9t\u00e9 int\u00e9gr\u00e9s \u00e0 son ADN : un anticorps anti-CTLA4 d\u00e9velopp\u00e9 par BioInvent et la cytokine GM-CSF pour activer la r\u00e9ponse immunitaire. &nbsp; D\u00e9truire de mani\u00e8re cibl\u00e9e les cellules canc\u00e9reuses &nbsp; D\u00e9couvrez comment fonctionne BT-001 (vid\u00e9o) *&hellip;\u2026","_links":{"self":[{"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/posts\/26631","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/comments?post=26631"}],"version-history":[{"count":39,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/posts\/26631\/revisions"}],"predecessor-version":[{"id":40690,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/posts\/26631\/revisions\/40690"}],"wp:attachment":[{"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/media?parent=26631"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/categories?post=26631"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/tags?post=26631"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}